



**Humane
World for
Animals™**



International Alliance for
Biological Standardization



AFSA
COLLABORATION

Animal testing replacement for vaccines. A One Health View: global outlook and future strategy.

An AFSA conference in collaboration with IABS
Bangkok, Thailand, December 2-4 2025

ABSTRACT

The Humane World for Animals and IABS have been collaborating together since the 2019 IABS conference “Animal Testing for Vaccines Implementing Replacement, Reduction and Refinement: Challenges and Priorities” ([Akkermans et al.](#)) and under the AFSA Collaboration since 2020. They successfully organized online and face to face meetings ([AFSA Collaborations Events](#)) to promote dialogue and joint actions on animal testing replacement for both human and veterinary vaccines. This conference wishes to bring together again all the stakeholders in the field with the scope to concretely discuss about future projects and policy changes that need to be implemented to successfully phase out the reliance on animal testing within the vaccines testing control strategy (including product development, CMC and release), including the importance of vaccines’ supply chain sustainability and continuity and the benefits of this in supporting the role of vaccines in One Health (ensuring animal health and food chain security, addressing zoonosis and emergency disease situations as well as the critical role of vaccines in reducing AMR).

Scientific Committee:

Elisabeth **Balks**, PEI, Germany
Patricia **Carneiro**, Butantan Foundation,
Brazil
Emmanuelle **Coppens**, Sanofi
Pradip **Das**, Biological E, India
Juliana **Gutierrez**, bioMérieux
Sunil **Goel**, Serum Institute of India
Carmen **Jungbäck**, IABS
Robin **Levis**, US FDA
Laurent **Mallet**, EDQM
Alexandrine **Maes**, WHO – NNB
Kutub **Mahmood**, PATH
Laura **Martinez**, Virbac, HealthforAnimals
Shawn **Novick**, IABS
Hendrik **Jan Ormel**, Chair of the Dutch
Central Committee on Animal Testing

Ray **Prasad**, Bill & Melinda Gates Foundation
Shahjahn **Shaid**, GSK
Gautam **Sanyal**, Vaccine Analytics, USA
Heidmarie **Schindl**, AGES, Austria
Dean **Smith**, HealthCanada
Paul **Stickings**, MHRA, UK
Catrina **Stirling**, Zoetis, HealthforAnimals
Joris **Vandeputte**, IABS
Geneviève **Waeterloos**, Sciensano, Belgium
Wipawee **Wongchana**, Institute of Biologicals
Products, Thailand
Irma **Riyanti**, Bio Farma, Indonesia
Jack **Xie**, J&J China

Organizing Committee:

Laura **Viviani**, SciEthiQ for Humane Society International
Madinina **Cox**, IABS Secretariat Director
Marlène **Louis**, IABS Secretariat

PROVISIONAL AGENDA

Day 1: Tuesday, December 2nd, 2025

Opening Remarks from the Animal Free Safety Assessment Collaboration (AFSA), the International Alliance for Biological Standardization (IABS) and the Institute of Biological Products, Ministry of Health of Thailand

OneHealth approach to advance control strategies to support vaccine sustainability

Bird's eye view on the last on the projects and achievements in the field

Industry perspective on future changes in the field and global alignment

Regulatory perspective: ongoing progresses in methods acceptance, update of legislations, regulations and guidelines

Workshop: How to build competence in new testing strategies in Regulatory Agencies Laboratories and strategies to streamline batch release strategies

Workshop: Safety Testing. Achievements and next steps for the implementation

Day 2: Wednesday, December 3rd, 2025

Development/qualification/control activities as critical steps to ensure quality/consistency: legacy and new products experiences from the CMC/Quality

Adjuvants and their impact on the in vitro release strategy

Role of the International Reference Standards for in vitro assays. Need of new standards or use of in house?

Validation, collaborative studies, product specific validation. All valuable approaches, choosing the right one is key for successful implementation and regulatory acceptance

Workshop: Potency Testing: Achievements and next steps for implementation

Roles of global health foundations on their potential role in funding / cost sharing for capital investment and training

Day 3: Thursday, December 4th, 2025 *(half day)*

Workshop: a new approach to pyrogenicity. How MAT and recombinant BET are changing the approach to pyrogenicity

A sustainable approach to reagents

Align agendas, roles and expertise: Networks, collaborations and their transformative role